Hers vs Ivim Health: Broad Platform vs Focused Program

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This review is editorially independent. PlexusDx has no commercial relationship with Hers or Ivim Health, earns nothing from either, and uses no affiliate links.

Hers and Ivim Health come at GLP-1 weight management from different origins. Hers is the consumer-facing side of a large multi-category telehealth platform; Ivim Health is a more metabolic, compounding-focused program. This overview compares how each is organized, how intake and fulfillment differ, and the genetic blueprint neither reads before a prescription is written. As of April 2026, dozens of programs exist; this focuses on the two in the query.

Hers within the Hims & Hers platform

Hers, part of Hims & Hers Health, runs as subscription telehealth spanning several wellness categories, with GLP-1 weight management one offering among many. Intake, provider review, and a prescription for a branded FDA-approved GLP-1 or compounded semaglutide or tirzepatide follow the platform pattern. Current details sit on the Hers website.

Ivim Health as a compounding-focused program

Ivim Health combines telehealth with a compounded-pharmacy pathway, routing prescriptions to a retail pharmacy for branded products or a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Its emphasis skews toward the metabolic program itself rather than a broad catalog; verify specifics on the Ivim Health website.

Comparing intake, provider access, and fulfillment

The differences worth weighing are practical: how the intake is structured, whether you reach a physician or an NP/PA, how titration and follow-up are handled, and which pharmacy partners fulfill the order. A broad platform and a focused program can each serve you well; the fit depends on whether you value breadth or a narrower metabolic focus.

The pharmacology both programs rely on

Neither brand invents its own pharmacology. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide drive the results, with evidence from STEP (NEJM 2021), SURMOUNT (NEJM 2022), and SURMOUNT-OSA (NEJM 2024). The compound and dose determine effect size, not the telehealth brand delivering them.

Matching platform breadth to your needs

Breadth cuts both ways. A wide platform like Hers can be convenient if you expect to use several services under one account and value a familiar interface across them. A focused program like Ivim Health may feel more attentive to the metabolic use case, with staff and workflows oriented around it. Neither is a proxy for quality; the deciding factor is whether your health needs are broad enough to reward a platform or specific enough to reward a program built around one goal.

The genetic blueprint neither program reads

Whether you choose a broad platform or a focused program, both stop at the prescription. A variant in MC4R, central to satiety and energy balance, together with FTO and GLP1R, maps the metabolic baseline a protocol acts on. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across that blueprint, and it does not predict response to any single compound.

A genetics-first alternative from PlexusDx

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, sold as Semaglutide Injection ($189/month), Semaglutide Oral, Tirzepatide Injection ($289/month), and Tirzepatide Oral. Running the Precision Peptide Genetic Test first supplies the blueprint that both platforms leave out.

Not affiliated: PlexusDx has no commercial relationship with Hers, Ivim Health, or any brand mentioned in this article.

Keep reading on PlexusDx: What Is GLP-1, GLP-1 What Is, GLP-1 Receptor Agonist, GLP-1 Drugs.

Editorial note: this comparison is educational. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is unaffiliated with the reviewed brands. The Precision Peptide Genetic Test reports genetic influence on peptide pathways and does not predict medication response. Consult a qualified provider before starting a protocol.

Frequently Asked Questions

Is Hers a dedicated weight program like Ivim Health?

Hers is part of a broad multi-category telehealth platform where GLP-1 weight management is one of several offerings, while Ivim Health leans toward a metabolic, compounding-focused program. Neither structure is inherently better; the right choice depends on whether you prefer breadth or a narrower focus.

Do Hers and Ivim Health use compounded medication?

Both can prescribe branded FDA-approved GLP-1 products or compounded semaglutide or tirzepatide from licensed pharmacies, subject to eligibility and supply. Which formulation you receive depends on the current catalog, so confirm the dispensing pathway on each brand own site before deciding.

Which program is easier to start with?

Both begin with an online intake and clinical review before any prescription. Ease of onboarding depends on the specific intake flow, provider availability, and fulfillment timing each currently offers, so compare the present experience on each website rather than assuming one is simpler.

How does genetic testing complement either choice?

Genetic testing adds an upstream layer neither program provides. The Precision Peptide Genetic Test maps variants such as MC4R and FTO that shape appetite and energy balance, giving you and your provider context that applies whether you pick a broad platform or a focused metabolic program.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education